The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today


Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate

November 13, 2021 - 10:14 -- Open Access
Sookpongthai P, Utayopas K, Sitthiyotha T, Pengsakul T, Kaewthamasorn M, Wangkanont K, Harnyuttanakorn P, Chunsrivirot S, Pattaradilokrat S
Parasit Vectors. 2021 Nov 8;14(1):571

Vaccines against the sexual stages of the malarial parasite Plasmodium falciparum are indispensable for controlling malaria and abrogating the spread of drug-resistant parasites. Pfs25, a surface antigen of the sexual stage of P. falciparum, is a leading candidate for transmission-blocking vaccine development. While clinical trials have reported that Pfs25-based vaccines are safe and effective in inducing transmission-blocking antibodies, the extent of the genetic diversity of Pfs25 in malaria endemic populations has rarely been studied. Thus, this study aimed to investigate the global diversity of Pfs25 in P. falciparum populations.

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine

October 16, 2021 - 12:22 -- Open Access
Singh SK, Plieskatt J, Theisen M, et al.
NPJ Vaccines. 2021 Oct 12;6(1):120

The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230-Pfs48/45 fusion protein elicits higher levels of functional antibodies than the individual antigens, but low yields hampered progression to clinical evaluation. Here we identified a modified construct (ProC6C) with a circumsporozoite protein (CSP) repeat-linker sequence that enhances expression.

NOT Open Access | Plasmodium falciparum Pf77 and male development gene 1 as vaccine antigens that induce potent transmission-reducing antibodies

June 16, 2021 - 14:59 -- NOT Open Access
Tripathi AK, Oakley MS, Kumar S, et al.
Sci Transl Med. 2021 Jun 9;13(597):eabg2112

Malaria vaccines that disrupt the Plasmodium life cycle in mosquitoes and reduce parasite transmission in endemic areas are termed transmission-blocking vaccines (TBVs). Despite decades of research, there are only a few Plasmodium falciparum antigens that indisputably and reproducibly demonstrate transmission-blocking immunity. So far, only two TBV candidates have advanced to phase 1/2 clinical testing with limited success.

NOT Open Access | Structural and immunogenicity analysis of reconstructed ancestral and consensus P48/45 for cross-species anti malaria transmission-blocking vaccine

June 9, 2021 - 14:16 -- NOT Open Access
Ramanto KN, Nurdiansyah R
Comput Biol Chem. 2021 Jun;92:107495

The development of the anti-malaria vaccine holds a promising future in malaria control. One of the anti-malaria vaccine strategies known as the transmission-blocking vaccine (TBV) is to inhibit the parasite transmission between humans and mosquitoes by targeting the parasite gametocyte. Previously, we found that P48/45 included in the 6-Cysteine protein family shared by Plasmodium sp. We also detected vaccine properties possessed by all human-infecting Plasmodium and could be used as a cross-species anti-malaria vaccine.

Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria

May 12, 2021 - 09:30 -- Open Access
Yang F, Liu F, Yu X, Zheng W, Wu Y, Qiu Y, Jin Y, Cui L, Cao Y
Parasit Vectors. 2021 May 7;14(1):241

Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually.

Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone

April 14, 2021 - 08:11 -- Open Access
Kaci D. McCoy, Caroline T. Weldon, Rashid Ansumana, Joseph M. Lamin, David A. Stenger, Sadie J. Ryan, Kevin Bardosh, Kathryn H. Jacobsen and Rhoel R. Dinglasan
Malaria Journal 2021 20:183, 13 April 2021

Malaria transmission-blocking vaccines (TBVs) could help break the cycle of malaria transmission by conferring community rather than individual protection. When introducing new intervention strategies, uptake is dependent on acceptability, not just efficacy. In this exploratory study on acceptability of TBVs in Sierra Leone, it was hypothesized that TBVs would be largely acceptable to adults and health workers in areas with relatively few ongoing malaria interventions, and that (i) knowledge of malaria and vaccines, (ii) health behaviours associated with malaria and vaccines, and (iii) attitudes towards different vaccines types could lead to greater TBV acceptability.

Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen

April 7, 2021 - 12:09 -- Open Access
Bender NG, Khare P, Dinglasan RR, et al.
NPJ Vaccines. 2021 Apr 6;6(1):49

Malaria transmission-blocking vaccines (TBVs) prevent the completion of the developmental lifecycle of malarial parasites within the mosquito vector, effectively blocking subsequent infections. The mosquito midgut protein Anopheline alanyl aminopeptidase N (AnAPN1) is the leading, mosquito-based TBV antigen. Structure-function studies identified two Class II epitopes that can induce potent transmission-blocking (T-B) antibodies, informing the design of the next-generation AnAPN1.

NOT Open Access | Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination

January 27, 2021 - 10:38 -- NOT Open Access
Duffy PE
Expert Rev Vaccines. 2021 Jan 22

Transmission-blocking vaccines (TBV) prevent community spread of malaria by targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in elimination programs. TBV rely on herd immunity to reduce mosquito infections and thereby new infections in both vaccine recipients and non-recipients, but do not provide protection once an individual receives an infectious mosquito bite which complicates clinical development.

NOT Open Access | Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development

January 16, 2021 - 09:16 -- NOT Open Access
Asali S, Raz A, Turki H, Mafakher L, Razmjou E, Solaymani-Mohammadi S
Infect Genet Evol. 2021 Jan 6:104710

Plasmodium vivax is the most widespread malaria species parasitizing humans outside Africa, with approximately 100 million cases reported per year. Most human cases of P. vivax are asymptomatic with low parasitemia, making active case detection-based elimination programme challenging and less effective. Despite the widespread distribution of P. vivax, no effective vaccines are currently available. Transmission blocking vaccines have recently emerged as potential vaccine candidates to reduce transmission rates to below the essential levels required for the maintenance of the parasite life cycle.

NOT Open Access | Structural vaccinology of malaria transmission-blocking vaccines

January 13, 2021 - 11:26 -- NOT Open Access
Patel PN, Tolia NH
Expert Rev Vaccines. 2021 Jan 11

The development of effective vaccines remains a major health priority to combat the global burden of malaria, a life-threatening disease caused by Plasmodium parasites. Transmission-blocking vaccines (TBVs) elicit antibodies that neutralize the sexual stages of the parasite in blood meals ingested by the Anopheles mosquito, interrupting parasite development in the vector host and preventing disease spread to other individuals.


Subscribe to RSS - TBV